Company · DXCM
DexCom, Inc.
Name as listed on its exchange; filed with the SEC as DEXCOM INC.
Nasdaq's symbol directory lists DXCM on Nasdaq as “DexCom, Inc. - Common Stock”.
In the 12 months to Nov 19, 2026: insiders sold on 19 occasions ($9.6M); 17 planned-sale notices; 1 filing by holders of 5% or more; 13 congressional trade disclosures; 4 company reports (Form 8-K, since May 26, 2026).
Insider trades · SEC Form 4
Those inside the hall
Open-market purchases and sales only. Legs one person filed for one day are combined.
Who traded
- Kevin R. Sayer, Executive Chair sold $6.4M
- Brown Michael Jon, EVP Chief Legal Compliance Off sold $841K
- AUGUSTINOS NICHOLAS sold $680K
- Stern Sadie, EVP Chief People & Culture Off sold $649K
- FOLETTA MARK G sold $627K
- Sylvain Jereme M, EVP, Chief Financal Officer sold $303K
- Heller Bridgette P sold $89K
Every trade (19)
- SELLBrown Michael Jon, EVP Chief Legal Compliance Off sold $142K
- SELLStern Sadie, EVP Chief People & Culture Off sold $202K
- SELLBrown Michael Jon, EVP Chief Legal Compliance Off sold $145K
- SELLStern Sadie, EVP Chief People & Culture Off sold $221K
- SELLAUGUSTINOS NICHOLAS sold $550K
- SELLBrown Michael Jon, EVP Chief Legal Compliance Off sold $143K
- SELLAUGUSTINOS NICHOLAS sold $130K
- SELLSylvain Jereme M, EVP, Chief Financal Officer sold $303K
- SELLStern Sadie, EVP Chief People & Culture Off sold $227K
- SELLKevin R. Sayer, Executive Chair sold $2.4M
- SELLBrown Michael Jon, EVP Chief Legal Compliance Off sold $156K
- SELLHeller Bridgette P sold $89K
- SELLFOLETTA MARK G sold $171K
- SELLFOLETTA MARK G sold $160K
- SELLKevin R. Sayer, Executive Chair sold $2.0M
- SELLBrown Michael Jon, EVP Chief Legal Compliance Off sold $127K
- SELLKevin R. Sayer, Executive Chair sold $1.9M
- SELLFOLETTA MARK G sold $297K
- SELLBrown Michael Jon, EVP Chief Legal Compliance Off sold $128K
Planned sales · SEC Form 144
Notice given
A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice
- MICHAEL BROWN $142K
- SADIE STERN $202K
- MICHAEL BROWN $145K
- SADIE STERN $221K
- AUGUSTINOS NICHOLAS $550K
- MICHAEL BROWN $143K
- AUGUSTINOS NICHOLAS $130K
- JEREME SYLVAIN $303K
- SADIE STERN $227K
- KEVIN R SAYER $2.4M
- MICHAEL BROWN $156K
- Heller Bridgette P $89K
- FOLETTA MARK G $171K
- FOLETTA MARK G $160K
- KEVIN R SAYER $2.0M
- MICHAEL BROWN $127K
- KEVIN R SAYER $1.9M
Large holders · SEC Schedules 13D and 13G
Five percent and over
Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G
- STATE STREET CORPORATION 5%
Congress · STOCK Act
The Althing
Periodic transaction reports. Amounts are the ranges members report; the trade date is when it happened, the report can come up to 45 days later.
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
- Rohit Khanna (D-CA17): Purchase $1,001 - $15,000
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
- Michael T. McCaul (R-TX10): Sale $1,001 - $15,000
- Tina Smith (D-MN): Sale (Full) $100,001 - $250,000
- Rohit Khanna (D-CA17): Purchase $1,001 - $15,000
- Tina Smith (D-MN): Sale (Partial) $100,001 - $250,000
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
- Rohit Khanna (D-CA17): Purchase $1,001 - $15,000
- Rohit Khanna (D-CA17): Sale $1,001 - $15,000
- Michael T. McCaul (R-TX10): Sale $1,001 - $15,000
- Rohit Khanna (D-CA17): Purchase $1,001 - $15,000
- John Boozman (R-AR): Purchase $1,001 - $15,000
Executive branch · OGE Form 278-T
Reported by the President
10 confirmed trades on scanned reports whose security name matches this company's own filed name exactly (letter case, punctuation and Inc/Corp-style endings aside). All of Donald J. Trump's reports
- Purchase: DEXCOM INC $1,001 – $15,000
- Purchase: DEXCOM INC $1,001 – $15,000
- Purchase: DEXCOM INC $1,001 – $15,000
- Purchase: DEXCOM INC $100,001 – $250,000
- Sale: DEXCOM INC $15,001 – $50,000
- Sale: DEXCOM INC $15,001 – $50,000
- Sale: DEXCOM INC $1,001 – $15,000
- Purchase: DEXCOM INC $15,001 – $50,000
- Sale: DEXCOM INC $1,001 – $15,000
- Purchase: DEXCOM INC $100,001 – $250,000
Company reports · SEC Form 8-K
In its own words
Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.
- Results of operations and financial condition; Other events Oct 29, 2026
- Departure or appointment of directors or officers; Regulation FD disclosure Sep 14, 2026
- Departure or appointment of directors or officers; Regulation FD disclosure Sep 10, 2026
- Results of operations and financial condition Jul 30, 2026
Lobbying · Senate LDA reports
Lobbying filed
9 quarterly lobbying reports for 2026 naming DexCom, Inc. as the client: 3 filed by the company itself, 6 by outside firms it hired. Each line is one report as filed; an amended report is a line of its own. An outside firm states what the company paid it; the company's own report states its whole lobbying spend, which can include those fees, so the lines are not added up. Reports are collected in batches and a quarter can be missing here; the full record is at lda.gov.
- The company itself $320K
- FARRAGUT PARTNERS LLP $50K
- ALSTON & BIRD LLP $40K
- The company itself $370K
- FARRAGUT PARTNERS LLP $50K
- ALSTON & BIRD LLP $40K
- The company itself $380K
- FARRAGUT PARTNERS LLP $50K
- ALSTON & BIRD LLP $40K
Sources: SEC EDGAR (Forms 4, 144 and 8-K), Senate LDA lobbying reports, OGE Form 278-T reports on whitehouse.gov and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.